Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Arrowhead Pharmaceuticals reports progress in diverse drug pipeline and partnerships

Arrowhead Pharmaceuticals showcased progress in its drug candidates, highlighted its commitment to expanding the TRiM platform, and emphasized its potential to address gene targets across multiple therapeutic areas. The company faces challenges in decision-making regarding partnerships and prioritizing internal versus external development, but sees opportunities in potential partnerships and evaluating additional indications for its assets.

Arrowhead Pharmaceuticals advances pipeline and de-risks pulmonary franchise

Arrowhead Pharmaceuticals reports progress in de-risking its pulmonary franchise and achieving promising results in chronic GLP tox studies. The company aims to expand its pipeline to 20 clinical stage or marketed products by 2025 and highlights strength in its pipeline and financial updates. However, challenges in partnering for cardiovascular assets and financing strategies are evident, while opportunities exist in advancing drug candidates and building a sustainable business.

Arrowhead Pharmaceuticals Advances Clinical Programs and Explores Financing Strategies

Arrowhead Pharmaceuticals has made significant progress in its clinical programs and is actively working on strengthening its balance sheet. The company is considering potential financing strategies and exploring licensing agreements and partnerships for various assets. With plans for Phase 3 studies for key products and a focus on commercial build-out, Arrowhead Pharmaceuticals is positioning itself for future growth.

Arrowhead Pharmaceuticals reports Q4 loss, focuses on cardiometabolic and pulmonary programs

Arrowhead Pharmaceuticals reported a net loss for the quarter but has a strong cash position after a recent capital raise. The company is focused on advancing its cardiometabolic and pulmonary programs, with promising results in its lead programs. While facing challenges with insufficient data and operating expenses, Arrowhead sees opportunities in new program filings and the transition into a commercial company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Amarin Corporation Plc

Intercept Pharma

Flushed with cash, bigger biotech stocks are on the hunt. These 3 smaller drug makers could be the next buyout targets in the new year.

3 Biotech Stocks to Bank on for Buyouts in 2020

The RNAi drug developer tickled investors with promising clinical data.

Here's Why Arrowhead Pharmaceuticals Stock Soared 410% in 2019

Buy Arrowhead Pharmaceuticals Now At Near The Institutional Discount

Dicerna Pharmaceuticals

These two promising RNAi drug developers are trading at hefty premiums going into 2020.

These 2 Stocks Will Fall After the New Year

ArQule

Eidos Therapeutics Inc

Guardant Health Inc

Kodiak Sciences Inc

Medpace Holdings

NeoGenomics

Nevro

Tenet Healthcare

Zoetis

Helping people stricken with illness can be richly rewarding in more ways than one.

These Were the 10 Best Healthcare Stocks of 2019

Blueprint Medicines

Deciphera Pharmaceuticals

They have what deep-pocketed pharmaceutical giants want.

3 Stocks - That Could Be the Next Biotech Buyouts.

Despite Arrowhead Pharmaceuticals' trouncing the market this year, there's one glaring weakness in its investment thesis at the moment.

Despite Massive Gains This Year, This Biotech Stock Is a Risky Bet

Now that the initial excitement has worn off, investors are correctly responding to the news of a public stock offering.

Here's Why Arrowhead Pharmaceuticals Is Tumbling Today

Counterintuitively, investors are bidding up the share price after the company announced a public stock offering.

Here's Why Arrowhead Pharmaceuticals Is Soaring Today

Innovative Industrial Properties

MercadoLibre

There's gambling, and then there are these businesses with solid prospects you can invest in.

Don't Waste Your Money on Penny Stocks; These 3 Companies Are Better Buys

Arrowhead Pharmaceuticals announced an underwritten offer for 4 million shares late Monday, causing ARWR stock to collapse before the close.

This Highly Rated Biotech Company Just Tumbled 13% On A Public Offering

ACADIA Pharma

China Biologic Products Holdings

Galapagos

Natera

Spark Therapeutics

Zai Lab Ltd.

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

7 Exciting Biotech Stocks to Buy Now

Adverum Biotechnologies

Here's how they could keep on rocketing higher.

3 Soaring Biotech Stocks to Watch in December

Arrowhead Pharmaceuticals grabbed an upgrade Friday as ARWR stock has rocketed 144% since October on enthusiasm for the biotech company's RNAi platform. ARWR stock is 87% above a buy point.

This Biotech With 456% Growth In 2019 Just Gained A Price-Target Boost

The gene-silencing specialist reported fiscal 2019 operating results and listed recent accomplishments.

Here's Why Arrowhead Pharmaceuticals Is Soaring (Again) Today

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2019 Results - Earnings Call Transcript

Lyft

Ferro

These stocks climbed more than most on a winning day on Wall Street.

Why Lyft, Arrowhead Pharmaceuticals, and Ferro Jumped Today

Clovis Oncology

Medicines

Sorrento Therapeutics Inc

A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?

The Return of M&A Activity Is Lifting These Biotech Stocks Today

Arrowhead Pharmaceuticals (NASDAQ: ARWR), a company that focuses on the treatment of intractable diseases by targeting the genes that cause them, has seen its stock rise by over 30% over the last month. The company currently has a pipeline of 9 drugs under clinical trials.

Why Arrowhead Pharma Stock Has Rallied 30% Over The Last Month

Inmode Ltd

InMode, Amarin, and Arrowhead Pharmaceuticals are small-cap healthcare stocks working wonders right now.

3 Top Healthcare Stocks to Buy in November

Assembly Biosciences

Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.

2 Promising Hepatitis B Drugs, 1 Clear Winner Among Investors

As the health care sector breaks higher, Arrowhead is in a leadership position, and buy signals suggest additional upside potential.

Arrowhead Shares Are Still Alerting Big Buy Signals

Arrowhead Pharmaceuticals and Johnson & Johnson said Friday they eradicated nearly all traces of hepatitis B virus in a study — sending Arrowhead careening toward another record high.

Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

Arrowhead Pharma stock flirted with a breakout Friday after the biotech company said it's experimenting with silencing multiple genes as well as moving into diseases outside the liver.

This Biotech Stock Hurdled A Genetic Barrier — And Flirted With A Breakout

The biopharma announced fiscal third-quarter 2019 operating results and multiple updates from the pipeline.

News for Arrowhead Pharmaceuticals Stock (ARWR)